Posted by Michael Wonder on 24 Feb 2019
Paladin Labs announces approval of Envarsus PA (tacrolimus prolonged-release tablets) in Canada
22 February 2019 - Paladin Labs and Endo today announced Health Canada's approval of Envarsus PA (tacrolimus prolonged-release tablets) for the prophylaxis of organ rejection in kidney or liver transplant adult patients (in combination with other immunosuppressants).
Envarsus PA is marketed in Canada by Paladin Labs.
Envarsus PA (tacrolimus prolonged-release tablets) is indicated for the prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients in combination with other immunosuppressants. Envarsus is currently marketed in Europe and in the US.
